Scott W W, Johnson D E, Schmidt J E, Gibbons R P, Prout G R, Joiner J R, Saroff J, Murphy G P
J Urol. 1975 Dec;114(6):909-11. doi: 10.1016/s0022-5347(17)67172-6.
The National Prostatic Cancer Project has randomized this study for endocrine-resistant prostatic cancer patients for treatment with standard hormonal or other therapies compared to 5-fluorouracil and cyclophosphamide. Both agents were found at the probability level of 0.05 to have a significant advantage over standard treatment in terms of objective response, subjective improvement and minimal toxicity. Additional chemotherapy protocols are currently under way. This randomized trial is the first report of such a national study completed to date. We are much encouraged by this program and believe that additional agents now under consideration will provide additionally encouraging results.
国家前列腺癌项目已将这项针对内分泌抵抗性前列腺癌患者的研究进行随机分组，比较标准激素疗法或其他疗法与5-氟尿嘧啶和环磷酰胺的疗效。在0.05的概率水平上发现，这两种药物在客观缓解、主观改善和最小毒性方面均比标准治疗具有显著优势。目前正在进行其他化疗方案。这项随机试验是迄今为止完成的此类全国性研究的首份报告。我们对该项目备受鼓舞，并相信目前正在考虑的其他药物将带来更令人鼓舞的结果。
